InvestorsHub Logo
Followers 87
Posts 6644
Boards Moderated 1
Alias Born 09/18/2009

Re: InfinitePhoenix4 post# 42013

Sunday, 03/03/2024 7:26:12 AM

Sunday, March 03, 2024 7:26:12 AM

Post# of 42756
There are worse problems to have than trying to figure out what will be the most valuable entity for Humanigen shareholders 🙂. You make some good points and I can understand your enthusiasm, which I share, for our success in Australia.

But, if the loaned shares are recalled, chances are it will be with news, and Humanigen's value could skyrocket well beyond the value of their subsidiaries or Taran, if that news is related to covid prevention/treatment authorization. And in that regard, I now see news from the UK Ministers accusing the Health Secretary, "...of withholding data that could link the Covid vaccine to excess deaths, and criticised a “wall of silence” on the topic.

A cross-party group has written to Victoria Atkins to sound alarm about the “growing public and professional concerns” at the UK’s rates of excess deaths since 2020."

https://www.yahoo.com/news/health-secretary-urged-release-data-181513423.html

I'm disappointed that the UK regulators did not act independently and much earlier to approve lenz for covid. So I'm glad to see pressure building on them in this regard. I think a study of lenz patients could actually show "decreased deaths" and negligible (or at least show a statistically significant lower level) of covid pneumonia reinfections.